Published in Diabetes Care on October 27, 2010
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematol (2015) 1.45
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry. Curr Cardiovasc Risk Rep (2011) 0.93
Validation of methods to control for immortal time bias in a pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes. J Epidemiol (2014) 0.85
Comment on: Suissa and Azoulay. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-2673. Diabetes Care (2013) 0.83
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. BMC Med (2014) 0.82
Diabetes, insulin and cancer risk. World J Diabetes (2012) 0.80
Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes. Biomed Res Int (2015) 0.78
Interactive effect of serum uric acid and total bilirubin for cardiovascular disease in Chinese patients with type 2 diabetes. Sci Rep (2016) 0.77
HDL cholesterol and cancer risk among patients with type 2 diabetes. Diabetes Care (2014) 0.77
Methodological challenges to control for immortal time bias in addressing drug effects in type 2 diabetes. World J Methodol (2015) 0.75
Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives. Ann Transl Med (2014) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol (2006) 8.05
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Invited commentary: propensity scores. Am J Epidemiol (1999) 7.81
Calculating measures of biological interaction. Eur J Epidemiol (2005) 6.82
AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res (2007) 6.36
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Diabetes and cancer. Endocr Relat Cancer (2009) 5.04
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab (2009) 3.98
Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes (2010) 3.77
Test for additive interaction in proportional hazards models. Ann Epidemiol (2007) 2.68
Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev (2009) 2.66
Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med (2008) 1.69
Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ (2008) 1.45
Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia (2007) 1.24
Linking diabetes and cancer: a consensus on complexity. Lancet (2010) 1.19
Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care (2009) 1.13
Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer (2008) 1.10
Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J Biol Chem (2009) 1.04
Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes (2009) 0.99
Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem (1998) 0.89
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet (2008) 9.39
Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature (2007) 8.03
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet (2011) 4.50
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet (2009) 4.11
Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes (2010) 3.77
Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes (2008) 3.45
Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ (2006) 3.02
A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet (2010) 2.81
Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet (2010) 2.75
Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. Diabetes Care (2007) 2.18
Fat redistribution and adipocyte transformation in uninephrectomized rats. Kidney Int (2008) 2.18
Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci (2013) 2.15
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care (2003) 1.78
Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med (2008) 1.69
Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care (2006) 1.68
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study. Clin Endocrinol (Oxf) (2009) 1.61
Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol (2008) 1.57
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc Natl Acad Sci U S A (2004) 1.56
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Replication and identification of novel variants at TCF7L2 associated with type 2 diabetes in Hong Kong Chinese. J Clin Endocrinol Metab (2007) 1.47
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ (2008) 1.45
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res (2013) 1.42
Drug-induced endocrine and metabolic disorders. Drug Saf (2007) 1.42
Roth spots in diabetes mellitus. Lancet (2003) 1.41
Construction of a prediction model for type 2 diabetes mellitus in the Japanese population based on 11 genes with strong evidence of the association. J Hum Genet (2009) 1.38
Association of the D8S282 marker near the lipoprotein lipase gene locus with systolic blood pressure in healthy Chinese subjects. J Hypertens (2002) 1.38
Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care (2007) 1.34
Implication of genetic variants near NEGR1, SEC16B, TMEM18, ETV5/DGKG, GNPDA2, LIN7C/BDNF, MTCH2, BCDIN3D/FAIM2, SH2B1, FTO, MC4R, and KCTD15 with obesity and type 2 diabetes in 7705 Chinese. J Clin Endocrinol Metab (2010) 1.34
Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol (2007) 1.32
Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care (2008) 1.32
European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS One (2010) 1.29
Genome-wide association study identifies three novel loci for type 2 diabetes. Hum Mol Genet (2013) 1.28
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Ghrelin--not just another stomach hormone. Regul Pept (2002) 1.22
Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes (2012) 1.20
Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Metab Res Rev (2008) 1.20
Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med (2005) 1.20
Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes (2004) 1.19